search
Back to results

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer (pyruvate)

Primary Purpose

Prostate Cancer

Status
Recruiting
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Pyruvate (13C)
Hyperpolarized 13C,15N2-urea
Magnetic Resonance Spectroscopic Imaging
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Prostate Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Biopsy-proven adenocarcinoma of the prostate; biopsy may be performed outside of University of California San Francisco (UCSF), if detailed results of sextant biopsy are available; a minimum of 20 patients out of a planned enrollment of 50 patients must have high-risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
  • Planned radical prostatectomy at UCSF within 12 weeks following protocol MRI/MRSI
  • The subject is able and willing to comply with study procedures and provide signed and dated informed consent
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Absolute neutrophil count (ANC) >= 1500 cells/uL
  • Hemoglobin >= 9.0 mg/dL
  • Platelets >= 75,000 cells/uL
  • Estimated creatinine clearance >= 50 mL/min (by the Cockcroft Gault equation)
  • Bilirubin < 1.5 x upper limit of normal (ULN) (unless Gilbert's is suspected)
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN

Exclusion Criteria:

  • Patients who because of general medical or psychiatric condition or physiologic status cannot give valid informed consent
  • Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips
  • Patients who cannot tolerate or have contra-indications to endorectal coil insertion; for example, patients with a prior abdominoperineal resection of the rectum or latex allergy
  • Patients with contra-indications to injection of gadolinium contrast; for example patients with prior documented allergy or those with inadequate renal function
  • Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging
  • Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment; no limit on number of prior prostate biopsies; prior transurethral prostatic resection (TURP) is not allowed
  • Current or prior androgen deprivation therapy; a history of use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry
  • Poorly controlled hypertension, with blood pressure at study entry > 160/100; the addition of anti-hypertensives to control blood pressure is allowed for eligibility determination
  • Congestive heart failure or New York Heart Association (NYHA) status >= 2
  • A history of clinically significant electrocardiography (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry; patients with rate-controlled atrial fibrillation/flutter will be allowed on study

Sites / Locations

  • University of California, San FranciscoRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Pre-surgical Prostate Cancer patients

Arm Description

Infusion of co-hyperpolarized 13C pyruvate and undergo and hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion High spatial resolution MRI/1H MRSI staging exam (PROSE) using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent radical prostatectomy. At least 20 patients will be required to have high risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy

Outcomes

Primary Outcome Measures

Mean peak intra-tumoral lactate/pyruvate (lac/pyr) ratio by Pathological grade
Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare lactate area under curve by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Mean lactate area under curve (AUC) by Pathological grade
Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare lactate area under curve by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Mean peak conversion of HP 13C pyruvate to lactate (kPL) by Pathological grade
Means and standard deviations for kPL will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare kPL by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Mean Urea AUC by Pathological grade
Means and standard deviations for Urea AUC will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare Urea AUC by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Mean urea transfer constant (Ktrans) by Pathological grade
Means and standard deviations for Ktrans will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare Ktrans by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).

Secondary Outcome Measures

Optimal cut-off value of peak lactate to pyruvate ratio (lac/pyr)
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of peak lac/pyr AUC on MRI that accurately detect primary Gleason 4 prostate cancer
Optimal cut-off value of lac/pyr area under the curve (AUC)
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of peak lac/pyr AUC values on MRI that accurately detect primary Gleason 4 prostate cancer
Optimal cut-off value of 13C pyruvate to lactate (kPL) rate
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of kPL on MRI that accurately detect primary Gleason 4 prostate cancer
Optimal cut-off value of urea AUC
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of urea AUC on MRI that accurately detect primary Gleason 4 prostate cancer
Optimal cut-off value of urea transfer constant (ktrans)
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of urea ktrans on MRI that accurately detect primary Gleason 4 prostate cancer
Proportion of participants with Treatment-Related Adverse Events
Assessment of the occurrence of clinically significant changes in safety variables from baseline. Safety endpoints include monitoring for the occurrence of treatment-emergent AEs. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) version 4.0.
Compare lactate/pyruvate area under curve (AUC) with Prostate Imaging Reporting and Data System (PI-RADS)
To compare lactate/pyruvate AUC on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Compare peak lactate/pyruvate with PI-RADS
To compare peak lactate/pyruvate on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Compare pyruvate to lactate (kPL) with PI-RADS
To compare peak pyruvate to lactate (kPL) on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Compare urea AUC with PI-RADS
To compare urea AUC on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Compare urea transfer constant (Ktrans) with PI-RADS
To compare urea ktrans on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Mean difference in Intra-patient peak lac/pyr
Intra-patient reproducibility of peak lac/pyr for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics
Mean difference in Intra-patient lac/pyr AUC
Intra-patient reproducibility of lac/pyr AUC for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics
Mean difference in Intra-patient kPL
Intra-patient reproducibility of kPL for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.
Mean difference in Intra-patient Urea AUC
Intra-patient reproducibility of Urea AUC for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.
Mean difference in Intra-patient Urea ktrans
Intra-patient reproducibility of Urea ktrans for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics

Full Information

First Posted
August 14, 2015
Last Updated
March 23, 2023
Sponsor
University of California, San Francisco
Collaborators
American Cancer Society, Inc., National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)
search

1. Study Identification

Unique Protocol Identification Number
NCT02526368
Brief Title
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
Acronym
pyruvate
Official Title
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
March 22, 2016 (Actual)
Primary Completion Date
December 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, San Francisco
Collaborators
American Cancer Society, Inc., National Cancer Institute (NCI), National Institute for Biomedical Imaging and Bioengineering (NIBIB)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This pilot clinical trial studies how well magnetic resonance spectroscopic imaging (MRSI) with hyperpolarized carbon C13 pyruvate works in finding prostate cancer that exhibits poorly differentiated or undifferentiated cells (high-grade) and that is restricted to the site of origin, without evidence of spread (localized) in patients undergoing radical prostatectomy. Diagnostic procedures, such as MRSI with hyperpolarized carbon C13 pyruvate, may aid in the diagnosis of prostate cancer and in discriminating high-grade from low-grade prostate cancer and benign adjacent prostate tissue
Detailed Description
PRIMARY OBJECTIVE: I. To investigate the association between hyperpolarized (HP) pyruvate-to-lactate conversion (kPL) and HP urea perfusion with histologic grade of prostate cancer, including benign prostate tissue, low grade disease (primary Gleason score < 4), and high grade (primary Gleason score >= 4) prostate cancer. SECONDARY OBJECTIVES: I. Safety. II. To determine the optimal cut-off value of peak lactate to pyruvate ratio (lac/pyr), lac/pyr area under the curve (AUC), 13C pyruvate to lactate (kPL) rate, urea AUC, and urea transfer constant (ktrans) on magnetic resonance imaging (MRI) that accurately detects primary Gleason 4 component cancer. III. To determine the reproducibility of peak lac/pyr, lac/pyr AUC and kPL, urea AUC and urea ktrans with same-day repeated dose studies. with same-day repeated dose studies. IV. To compare peak lac/pyr, lac/pyr AUC and kPL, urea AUC, urea ktrans on MRI with Prostate Imaging-Reporting and Data System (PI-RADS) assessment of multiparametic MRI in predicting regions of cancer versus benign tissue. EXPLORATORY OBJECTIVES: I. To correlate histologic markers, including lactate dehydrogenase A (LDHA) expression and activity level, along with Ki-67, MYC, and MCT 1 and 4 expression, with peak intra-tumoral lac/pyr ratio, lactate AUC, and kPL detected using anatomically aligned magnetic resonance (MR) cross-sectional images of the prostate gland. II. To test for an association between mean intra-tumoral lac/pyr signal and lactate AUC, kPL, urea AUC, and urea ktrans with adverse clinical and pathologic characteristics including extracapsular extension, positive nodal involvement, and failure to achieve undetectable prostate specific antigen (PSA) nadir following prostatectomy. OUTLINE: Patients receive hyperpolarized carbon C 13 pyruvate and urea C-13 intravenously (IV) and undergo MRSI within 12 weeks before undergoing radical prostatectomy. Patients may receive optional second hyperpolarized carbon C 13 pyruvate injection and undergo MRSI within 15-60 minutes after first scan. After completion of study, patients are followed up at 24 hours.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Prostate Cancer

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
50 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Pre-surgical Prostate Cancer patients
Arm Type
Experimental
Arm Description
Infusion of co-hyperpolarized 13C pyruvate and undergo and hyperpolarized 13C, 15N urea injection prior to metabolic/perfusion High spatial resolution MRI/1H MRSI staging exam (PROSE) using both a phased-array abdominal coil and an endorectal coil will be performed within 12 weeks of subsequent radical prostatectomy. At least 20 patients will be required to have high risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy
Intervention Type
Drug
Intervention Name(s)
Pyruvate (13C)
Other Intervention Name(s)
Hyperpolarized Pyruvate (13C)
Intervention Description
Given IV
Intervention Type
Drug
Intervention Name(s)
Hyperpolarized 13C,15N2-urea
Other Intervention Name(s)
Urea C-13, C13 Urea
Intervention Description
Given IV
Intervention Type
Procedure
Intervention Name(s)
Magnetic Resonance Spectroscopic Imaging
Other Intervention Name(s)
MRSI, MRS, 1H- Nuclear Magnetic Resonance Spectroscopic Imaging, MRS Imaging
Intervention Description
Undergo MRSI
Primary Outcome Measure Information:
Title
Mean peak intra-tumoral lactate/pyruvate (lac/pyr) ratio by Pathological grade
Description
Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare lactate area under curve by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Time Frame
Baseline, 1 day
Title
Mean lactate area under curve (AUC) by Pathological grade
Description
Means and standard deviations for lactate area under curve will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare lactate area under curve by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Time Frame
Baseline, 1 day
Title
Mean peak conversion of HP 13C pyruvate to lactate (kPL) by Pathological grade
Description
Means and standard deviations for kPL will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare kPL by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Time Frame
Baseline, 1 day
Title
Mean Urea AUC by Pathological grade
Description
Means and standard deviations for Urea AUC will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare Urea AUC by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Time Frame
Baseline, 1 day
Title
Mean urea transfer constant (Ktrans) by Pathological grade
Description
Means and standard deviations for Ktrans will be calculated by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)). A One-way ANOVA model will be used to compare Ktrans by pathologic grade (benign, low grade (primary Gleason score <4) and high grade (primary Gleason score >4)).
Time Frame
Baseline, 1 day
Secondary Outcome Measure Information:
Title
Optimal cut-off value of peak lactate to pyruvate ratio (lac/pyr)
Description
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of peak lac/pyr AUC on MRI that accurately detect primary Gleason 4 prostate cancer
Time Frame
Baseline, 1 day
Title
Optimal cut-off value of lac/pyr area under the curve (AUC)
Description
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of peak lac/pyr AUC values on MRI that accurately detect primary Gleason 4 prostate cancer
Time Frame
Baseline, 1 day
Title
Optimal cut-off value of 13C pyruvate to lactate (kPL) rate
Description
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of kPL on MRI that accurately detect primary Gleason 4 prostate cancer
Time Frame
Baseline, 1 day
Title
Optimal cut-off value of urea AUC
Description
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of urea AUC on MRI that accurately detect primary Gleason 4 prostate cancer
Time Frame
Baseline, 1 day
Title
Optimal cut-off value of urea transfer constant (ktrans)
Description
Receiver-operative-curve analyses will be performed to determine the optimal cut-point of urea ktrans on MRI that accurately detect primary Gleason 4 prostate cancer
Time Frame
Baseline, 1 day
Title
Proportion of participants with Treatment-Related Adverse Events
Description
Assessment of the occurrence of clinically significant changes in safety variables from baseline. Safety endpoints include monitoring for the occurrence of treatment-emergent AEs. Toxicities will be graded using the National Cancer Institute (NCI) Common Terminology (Toxicity) Criteria for Adverse Events (CTCAE) version 4.0.
Time Frame
Baseline, 1 day
Title
Compare lactate/pyruvate area under curve (AUC) with Prostate Imaging Reporting and Data System (PI-RADS)
Description
To compare lactate/pyruvate AUC on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Time Frame
Baseline, 1 day
Title
Compare peak lactate/pyruvate with PI-RADS
Description
To compare peak lactate/pyruvate on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Time Frame
Baseline, 1 day
Title
Compare pyruvate to lactate (kPL) with PI-RADS
Description
To compare peak pyruvate to lactate (kPL) on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Time Frame
Baseline, 1 day
Title
Compare urea AUC with PI-RADS
Description
To compare urea AUC on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Time Frame
Baseline, 1 day
Title
Compare urea transfer constant (Ktrans) with PI-RADS
Description
To compare urea ktrans on MRI with PI-RADS assessment of multiparametric MRI in predicting regions of cancer versus benign tissue. Radiologists use the PI-RADS to report how likely it is that a suspicious area is a clinically significant cancer. PI-RADS scores range from 1 (most likely not cancer) to 5 (very suspicious).
Time Frame
Baseline, 1 day
Title
Mean difference in Intra-patient peak lac/pyr
Description
Intra-patient reproducibility of peak lac/pyr for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics
Time Frame
Baseline, 1 day
Title
Mean difference in Intra-patient lac/pyr AUC
Description
Intra-patient reproducibility of lac/pyr AUC for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics
Time Frame
Baseline, 1 day
Title
Mean difference in Intra-patient kPL
Description
Intra-patient reproducibility of kPL for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.
Time Frame
Baseline, 1 day
Title
Mean difference in Intra-patient Urea AUC
Description
Intra-patient reproducibility of Urea AUC for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics.
Time Frame
Baseline, 1 day
Title
Mean difference in Intra-patient Urea ktrans
Description
Intra-patient reproducibility of Urea ktrans for patients who undergo repeated dose imaging studies, as descriptively reported using summary statistics
Time Frame
Baseline, 1 day

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Biopsy-proven adenocarcinoma of the prostate; biopsy may be performed outside of University of California San Francisco (UCSF), if detailed results of sextant biopsy are available; a minimum of 20 patients out of a planned enrollment of 50 patients must have high-risk disease as defined by primary Gleason score of 4 or 5 on prior prostate biopsy Planned radical prostatectomy at UCSF within 12 weeks following protocol MRI/MRSI The subject is able and willing to comply with study procedures and provide signed and dated informed consent Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Absolute neutrophil count (ANC) >= 1500 cells/uL Hemoglobin >= 9.0 mg/dL Platelets >= 75,000 cells/uL Estimated creatinine clearance >= 50 mL/min (by the Cockcroft Gault equation) Bilirubin < 1.5 x upper limit of normal (ULN) (unless Gilbert's is suspected) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN Exclusion Criteria: Patients who because of general medical or psychiatric condition or physiologic status cannot give valid informed consent Patients unwilling or unable to undergo MR imaging, including patients with contra-indications to MRI, such as cardiac pacemakers or non-compatible intracranial vascular clips Patients who cannot tolerate or have contra-indications to endorectal coil insertion; for example, patients with a prior abdominoperineal resection of the rectum or latex allergy Patients with contra-indications to injection of gadolinium contrast; for example patients with prior documented allergy or those with inadequate renal function Metallic hip implant or any other metallic implant or device that distorts local magnetic field and compromises the quality of MR imaging Cryosurgery, surgery for prostate cancer, prostatic or pelvic radiotherapy prior to study enrollment; no limit on number of prior prostate biopsies; prior transurethral prostatic resection (TURP) is not allowed Current or prior androgen deprivation therapy; a history of use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least one month prior to study entry Poorly controlled hypertension, with blood pressure at study entry > 160/100; the addition of anti-hypertensives to control blood pressure is allowed for eligibility determination Congestive heart failure or New York Heart Association (NYHA) status >= 2 A history of clinically significant electrocardiography (EKG) abnormalities, including QT prolongation, a family history of prolonged QT interval syndrome, or myocardial infarction (MI) within 6 months of study entry; patients with rate-controlled atrial fibrillation/flutter will be allowed on study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Louise Magat
Phone
877-827-3222
Email
Louise.Magat@ucsf.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rahul Aggarwal, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94143
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Louise Magat
Email
Louise.Magat@ucsf.edu
Phone
877-827-3222
Email
cancertrials@ucsf.edu
First Name & Middle Initial & Last Name & Degree
Rahul Aggarwal, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer

We'll reach out to this number within 24 hrs